1-[(2R,3R,4R,5S)-5-({[(S)-({[(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3-hydroxy-4-(phosphonooxy)oxolan-2-yl]methoxy}(hydroxy)phosphoryl phosphonato)]oxy}methyl)-3,4-dihydroxyoxolan-2-yl]-3-carbamothioyl-1$l^{5}-pyridin-1-ylium

• ChemBase编号: 1536
• 分子式: C21H28N7O16P3S
• 平均质量: 759.470603
• 单一同位素质量: 759.05260874
• SMILES: NC(=S)c1ccc[n+](c1)[C@@H]1O[C@@H](COP(=O)([O-])O[P@](=O)(O)OC[C@@H]2O[C@H]([C@H](OP(=O)(O)O)[C@H]2O)n2cnc3c2ncnc3N)[C@H](O)[C@H]1O
• Canonical SMILES: O[C@@H]1[C@@H](O)[C@@H](O[C@H]1[n+]1cccc(c1)C(=S)N)COP(=O)(O[P@@](=O)(OC[C@@H]1O[C@H]([C@@H]([C@H]1O)OP(=O)(O)O)n1cnc2c1ncnc2N)O)[O-]
• InChI: InChI=1S/C21H28N7O16P3S/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(43-45(32,33)34)14(30)11(42-21)6-40-47(37,38)44-46(35,36)39-5-10-13(29)15(31)20(41-10)27-3-1-2-9(4-27)18(23)48/h1-4,7-8,10-11,13-16,20-21,29-31H,5-6H2,(H7-,22,23,24,25,32,33,34,35,36,37,38,48)/t10-,11-,13-,14-,15+,16+,20+,21+/m0/s1
• InChIKey: OJNFDOAQUXJWED-XCSFTKGKSA-N

名称和登记号

名称

• IUPAC标准名: 1-[(2R,3R,4R,5S)-5-({[(S)-({[(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3-hydroxy-4-(phosphonooxy)oxolan-2-yl]methoxy}(hydroxy)phosphoryl phosphonato)]oxy}methyl)-3,4-dihydroxyoxolan-2-yl]-3-carbamothioyl-1$l^{5}-pyridin-1-ylium
• IUPAC传统名: @tatp
• 别名: Tatp

登记号

• CAS号: 17088-37-8
• PubChem SID: 160964993; 46506464
• PubChem CID: 46936208

理论计算性质

JChem

• Acid pKa: 0.65010595
• 质子受体: 16
• 质子供体: 8
• LogD (pH = 5.5): -12.904327
• LogD (pH = 7.4): -14.626846
• Log P: -10.573486
• 摩尔折射率: 159.739 cm^3
• 极化性: 63.929028 Å^3
• 极化表面积: 350.55 Å^2
• 可自由旋转的化学键: 13
• 里宾斯基五规则: false

ALOGPS 2.1

• Log P: -0.61
• LOG S: -2.58
• 溶解度: 2.14e+00 g/l

详细说明

DrugBank - DB01763

Drug information: experimental